CAR T Anti-GD2 Shows Promise in Paediatric Neuroblastoma

Children with a low disease burden have a 77% response rate and 68% 5-year overall survival.
Medscape News UK

source https://www.medscape.com/viewarticle/car-t-anti-gd2-shows-promise-paediatric-neuroblastoma-2025a1000nzs?src=rss